About us
TRIPEP develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform.
Tripep collaborates with research teams at two of Sweden's most renowned research institutions; the Karolinska Institute and the University of Uppsala. Experimental research is conducted at university laboratories, while the more industrial research is conducted at Tripep's laboratories at the Novum Research Park in Huddinge, near Stockholm, Sweden.
The share is quoted on First North. Remium AB is Certified Adviser for Tripep AB.